ASX:RGS), a clinical-stage regenerative medicine company, today provides an update on its negotiations with Kyocera Corporation (TYO:6971) for a licence agreement to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan (see previous announcements of 2 March 2020, 20 March 2020 and 18 May 2020). Under the terms of the MOU signed with Kyocera on 2 March 2020, Kyocera has exclusive rights to negotiate a commercial licence for Progenza in Japan. Under the terms of the MOU, that period of exclusivity currently extends to the end of July 2020.
The negotiations have progressed positively with a view on agreeing final terms. Both parties remain committed to the proposed commercial licence and the parties have agreed to extend the period of exclusivity, such that Kyocera will continue to have exclusive rights to negotiate the licence until 31 August 2020.
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Contact
WE CommunicationsT: +61-2-9237-2805
E: WE-AURegeneus@we-worldwide.com
Related Companies
